{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093992","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.963682+00:00","generated_at":"2026-05-31T10:58:34.641340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"4DMT reports Q2 net loss $35M, cash $578M; positive 4D-150 interim data; FDA lifts clinical hold on 4D-310","bullets":["Cash and equivalents $578M as of June 30, 2024; expected to fund operations into H1 2027.","Q2 net loss $35.0M vs $29.6M YoY; R&D expenses rose to $31.9M from $23.6M.","Phase 2 PRISM 4D-150 in wet AMD: 89% reduction in annualized anti-VEGF injections; 77% injection-free at 24 weeks with 3E10 vg/eye dose.","FDA removed clinical hold on Phase 1/2 INGLAXA trial for 4D-310 in Fabry disease cardiomyopathy; enrollment to resume H2 2024.","Senior leadership added: Dhaval Desai (CDO), Christopher Simms (CCO), Carlos Quezada-Ruiz (SVP Ophth); Ophthalmology Advisory Board formed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093992","json":"https://secwatch.observer/filing/0000950170-24-093992.json","markdown":"https://secwatch.observer/filing/0000950170-24-093992.md","text":"https://secwatch.observer/filing/0000950170-24-093992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024093992/0000950170-24-093992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024093992/fdmt-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:58:34.641340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}